Project Grant R01DK144460
Award Date 9/5/25
Completion Date 8/31/28
Dollars Obligated $2.3M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
- This federal Project Grant award of $801,662, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research by the Scripps Research Institute to investigate the early phase of type 1 diabetes. The key objectives are to characterize the antigen-presenting cells associated with pancreatic islets during the pre-diabetic stage in mice, using advanced techniques...
- This $120,255 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate the impact of antigen-specific immunotherapy on the differentiation and function of effector T cells in autoimmune diabetic islet transplants. The study aims to determine how inducing tolerance to a hybrid insulin peptide can expand antigen-specific regulatory T cells that suppress autoreactive CD4 and CD8 T...
- This $372,067 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of an immune evasive stem cell line for type 1 diabetes regenerative therapy. The grant recipient, Aleutian Therapeutics, Inc., a biotechnology company in Los Angeles, California, is conducting research to create gene editing technologies that enable allogeneic...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $455,491 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of North Carolina at Chapel Hill. This grant will fund a 5-year research project to investigate the role of T follicular helper cells (Tfh) in regulating T cell-mediated autoimmunity in type 1 diabetes. The research aims to characterize changes in islet Tfh as the disease...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,258 to The Leland Stanford Junior University to conduct research aimed at advancing cell-based therapies for Type 1 Diabetes Mellitus (T1D). The key objectives are to: 1) establish effective, non-toxic strategies to induce immune tolerance toward donor tissues for islet cell...
- This federal Cooperative Agreement award, with a total funding amount of $1,207,770.00 and an award date of January 1, 2025, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support research to investigate the role of genetically-controlled thymic epithelial cell (TEC) and hematopoietic stem cell (HSC) abnormalities in driving the development...
- This Cooperative Agreement award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,108,154 to develop a stem cell-based multi-cellular platform that integrates diverse types of immune cells with stem cell-derived islets. The goal is to create an improved preclinical research model to accelerate the development of therapeutic interventions for Type 1...
- This Project Grant award of $634,984 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of a specific B cell subset, termed BND2, in the autoimmune disorder type 1 diabetes (T1D). The research aims to: 1) elucidate the mechanism by which these insulin-reactive BND2 cells become activated and break anergy, 2) determine their fate and function as antigen-presenting...
- This $681,562 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate approaches for enhancing the metabolic maturity and functionality of human pluripotent stem cell-derived islet organoids, with the goal of improving their survival and efficacy for transplantation as a treatment for type 1 diabetes. The research will examine the use of pharmacological agents...